Opinion

Video

Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC

Author(s):

Heather A. Wakelee, MD, FASCO,Jacob Sands, MD

Panelists discuss the specific factors that influence the decision to initiate one of the NCCN guideline–preferred RET inhibitors, selpercatinib or pralsetinib, over the other in the treatment of RET fusion–positive NSCLC.

  • Dr Wakelee to Dr Sands: What specific factors aid in your decision to initiate one of the NCCN guideline–preferred RET inhibitors (selpercatinib and pralsetinib) over the other?
Related Videos
2 experts are featured in this series.
Related Content